Study details
Enrolling now
SPI-1005 in Adults with Cochlear Implants
Sound Pharmaceuticals, Incorporated
NCT IDNCT06340633ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
40
Study length
about 4 months
Ages
18+
Locations
1 site in SC
About this study
Researchers are testing whether the drug SPI-1005 is safe and well-tolerated in adults who have a cochlear implant. The trial also aims to see if SPI-1005 can help prevent or treat certain side effects after getting a cochlear implant. Participants will take either SPI-1005 or a placebo for 6 months, starting two days before receiving the cochlear implant.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ebselen
- 2.Take Placebo
PhasePhase 2
Primary goalNumber of Participants with Treatment Emergent Adverse Events (TEAE)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Number of Participants with Treatment Emergent Adverse Events (TEAE)